Susanne Antonie Schaffert
Director/Board Member chez INCYTE CORPORATION
Fortune : 14 M $ au 31/03/2024
Profil
Susanne Antonie Schaffert is an Independent Director at Incyte Corp.
and an Independent Non-Executive Director at Galapagos NV.
She is also a Director at Novo Holdings AS (Denmark) and a Member-Supervisory Board at CIBA Vision GmbH (Germany).
Previously, she served as the President & Chief Executive Officer at Novartis Oncology, Inc. from 2019 to 2022 and as the Chairman & President at Advanced Accelerator Applications SA in 2018-2019.
She was also a Director at Endocyte, Inc. and Rubius Therapeutics, Inc. She worked as the Head-Global Investor Relations at Novartis AG.
Schaffert holds graduate and doctorate degrees from Friedrich-Alexander University of Erlangen-Nuremberg.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NOVARTIS AG
0,01% | 31/12/2022 | 142 844 ( 0,01% ) | 14 M $ | 31/03/2024 |
INCYTE CORPORATION
0,00% | 14/06/2023 | 10 393 ( 0,00% ) | 592 089 $ | 31/03/2024 |
GALAPAGOS NV
0,00% | 15/03/2024 | 360 ( 0,00% ) | 11 501 $ | 31/03/2024 |
Postes actifs de Susanne Antonie Schaffert
| Sociétés | Poste | Début |
|---|---|---|
| INCYTE CORPORATION | Director/Board Member | 01/10/2022 |
| GALAPAGOS NV | Director/Board Member | 12/06/2023 |
CIBA Vision GmbH (Germany)
 CIBA Vision GmbH (Germany) Electronic ComponentsElectronic Technology Part of Alcon AG, CIBA Vision GmbH is a private company based in Grosswallstadt, Germany. CIBA Vision GmbH manufactures and markets contact lenses. The German company was founded in 1983. The CEO is Norbert Dörr. | Director/Board Member | - |
Novo Holdings AS (Denmark)
 Novo Holdings AS (Denmark) MiscellaneousMiscellaneous Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Director/Board Member | - |
Anciens postes connus de Susanne Antonie Schaffert
| Sociétés | Poste | Fin |
|---|---|---|
| RUBIUS THERAPEUTICS | Director/Board Member | 31/01/2023 |
Novartis Oncology, Inc.
 Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Chief Executive Officer | 01/04/2022 |
| ADVANCED ACCELERATOR APPLICATION SA(ADR) | Chairman | 01/02/2019 |
| ENDOCYTE, INC. | Director/Board Member | 21/12/2018 |
| NOVARTIS AG | Investor Relations Contact | - |
Formation de Susanne Antonie Schaffert
| Friedrich-Alexander University of Erlangen-Nuremberg | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| INCYTE CORPORATION | Health Technology |
| GALAPAGOS NV | Health Technology |
| NOVARTIS AG | Health Technology |
| Entreprise privées | 6 |
|---|---|
Novartis Oncology, Inc.
Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Health Technology |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) MiscellaneousMiscellaneous Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Miscellaneous |
Endocyte, Inc.
 Endocyte, Inc. Pharmaceuticals: MajorHealth Technology Endocyte, Inc. engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN. | Health Technology |
Advanced Accelerator Applications SA
 Advanced Accelerator Applications SA Medical SpecialtiesHealth Technology Advanced Accelerator Applications SA is a radiopharmaceutical company, which develops, produces and commercializes molecular nuclear medicine products. The firm offers research and development in medicinal and pharmaceutical therapeutic products mainly focusing in cardiology and neurology. It manufactures both diagnostic and therapeutic MNM products for commercialization. The company was founded by Stefano Buono in 2002 and is headquartered in Rueil-Malmaison Cedex, France. | Health Technology |
Rubius Therapeutics, Inc.
 Rubius Therapeutics, Inc. BiotechnologyHealth Technology Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines. It provides medicine for cancer, autoimmune diseases, hemophilia, infectious and metabolic diseases. The company was founded on April 26, 2013 and is headquartered in Foxboro, MA. | Health Technology |
CIBA Vision GmbH (Germany)
CIBA Vision GmbH (Germany) Electronic ComponentsElectronic Technology Part of Alcon AG, CIBA Vision GmbH is a private company based in Grosswallstadt, Germany. CIBA Vision GmbH manufactures and markets contact lenses. The German company was founded in 1983. The CEO is Norbert Dörr. | Electronic Technology |
